Menu
← Oncology Approval Tracker
FDA DECISION ·
Loqtorzi
toripalimab-tpzi · Coherus BioSciences
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Single-agent treatment for adults with recurrent unresectable or metastatic nasopharyngeal carcinoma that progressed during or after platinum-containing chemotherapy.
LAMPGEN ANALYSIS
Why it matters
A separate indication allowed monotherapy in the post-platinum setting.
What research teams should watch
Document the timing of progression relative to platinum and apply the single-agent evidence to the intended treatment line.
PRIMARY RECORDS